Transcript 1999 - SWGDRUG

Sandra E. Rodriguez-Cruz, Ph.D., ABC-F
SWGDRUG Secretariat
AAFS – Feb 26, 2016
History
O 1997 DEA and ONDCP co-sponsored
formation of TWGDRUG
O 1999 First meeting in Washington, DC
O 1999 SWGDRUG name adopted
O 2001 1st Edition of Recommendations
O 2014 OSAC established (Seized Drugs)
O 2015 Version 7.1 of Recommendations (draft)
2
Mission
To improve the quality of the forensic examination of
seized drugs and to respond to the needs of the
forensic community by supporting the development of
internationally accepted minimum standards,
identifying best practices within the international
community, and providing resources to help
laboratories meet these standards.
Current Documents
O SWGDRUG Recommendations v 7.1 (draft)
O Supplemental Documents:
O SD-1 - A Code of Professional Practice for
Drug Analysts
O SD-2 - Validation of Analytical Methods
O SD-3 - Examples of Measurement
Uncertainty for Weight Determinations
O SD-4 - Examples of Measurement Uncertainty
for Purity Determinations
O SD-5 - Reporting Examples
4
Current Resources
O MS Library
O Over 2,300 compounds (Version 2.4 Dec 2015)
O All spectra collected using EI-MS systems
O Several formats (Agilent Tech., Shimadzu, etc.)
O IR Library
O All spectra collected using FTIR-ATR system
O DEA Special Testing and Research Lab
O Several formats (Omnic, PE, etc.)
O Drug Monographs
O Over 250 available
O DEA Special Testing and Research Lab
5
ASTM Documents
O OSAC Seized Drugs Subcommittee has voted to
forward the following SWGDRUG –developed
documents to the OSAC Registry of Standards:
O E2329:
Identification of Seized Drugs
O E2548:
Sampling Seized Drugs for Qualitative and
Quantitative Analysis – in revision
O E2326:
Education and Training of Seized-Drug
Analysts
O E2327:
Quality Assurance of Laboratories
Performing Seized-Drug Analysis
6
ASTM Documents
O These SWGDRUG-developed documents will also be
considered by OSAC Seized Drugs Subcommittee:
O E2549:
Validation of Seized-Drugs Analytical
Methods – in revision
O E2764:
Uncertainty Assessment in the Context of
Seized Drug Analysis – in revision
O E2882:
Analysis of Clandestine Laboratory Evidence
7
2015 Summary
O In-person meeting – June 2015
O SWGDRUG Rec. v 7.1 – In revision
O Part IIIB
O Part IVB
O Supplemental Documents:
O Validation of qualitative methods
O Uncertainty for net weight extrapolations
8
SWGDRUG Recommendations
Category A
Category B
Category C
IR
CE
Color Tests
MS
GC
Fluorescence
NMR
IMS
Immunoassay
Raman
LC
Melting Point
X-ray Diffractometry
Microcrystalline Tests
UV
Pharmaceutical ID
TLC
Cannabis only:
Macro Examination
Micro Examination
9
SWGDRUG Recommendations
O Part IIIB – Drug Identification
O Categorization of analytical techniques
O Consideration of new technologies
O No changes to categories, but further
guidance
O Address different operation modes and
variations within a technique
O How their categorization can be affected
10
SWGDRUG Recommendations
O Part IVB – Validation of Analytical Methods
O Clarification on performance characteristics that
should be evaluated when validating a qualitative
method
O Repeatability, accuracy, LOD, etc.
O Documentation needed for validation
O Examples (supplemental document):
O GC-MS drug screen
O Color test
11
Supplemental Document SD-6
O Measurement Uncertainty for Net Weight or
Unit Count Extrapolation
O Three (3) scenarios
1. NW extrapolation based on non-statistical
sampling of population
2. NW extrapolation based on hypergeometric
sampling of population
3. Unit count extrapolation based on non-statistical
sampling (direct NW)
12
SWGDRUG Document Process
O Development
O Drafted by subcommittees
O Reviewed by core committee
O Public comments (60 days)
O Drafts revised, as needed
O Voted by core committee
O Dissemination
O www.swgdrug.org
13
Future Directions
O SWGDRUG meetings:
O Core committee (national & international)
O DEA – financial support
O Provide resources:
O Recommendations
O Supplemental documents
O Libraries and monographs
O Support the development of internationally
accepted minimum standards for the analysis of
seized drugs (OSAC)
14
www.SWGDRUG.org
15
SWGDRUG Core Committee
O DEA – Scott R. Oulton (Chair)**
O SAFS – Christian Matchett (Vice Chair)**
O DEA & AAFS – Dr. Sandra Rodriguez-Cruz1**
O MAFS – Richard Paulas**
O MAAFS – vacancy
O NEAFS – Tiffany Ribadeneyra**
O NWAFS & CAC – Sandra Sachs**
O SWAFS – Roger Schneider
O Educator – Dr. Eric Person**
O FBI – Pamela Reynolds
1non-voting
16
SWGDRUG Core Committee
O ASCLD – Garth Glassburg**
O NIST – Karen Phinney
O AFSN/IDWG – Dr. Angeline Yap Tiong Whei
O AICEF – Dr. Adriano Maldaner
O Australia – Catherine Quinn
O Canada – Richard Laing
O ENFSI – Dr. Michael Bovens
O Germany – Dr. Udo Zerell
O United Kingdom – Dr. Sylvia Burns
O UNODC – Dr. Conor Crean
17
Thank You!
O www.swgdrug.org
O [email protected]
18